Related Experiment Videos
Inhaled nitric oxide therapy in children
John P Kinsella1, Steven H Abman
1Department of Pediatrics, The Children's Hospital and the University of Colorado School of Medicine, Pediatric Heart-Lung Center, Section of Neonatology, Box B-070, 1056 E. 19th Ave., Denver, CO 80218-1088, USA. john.kinmsella@uchsc.edu
Paediatric Respiratory Reviews
|September 13, 2005
Summary
Inhaled nitric oxide (iNO) therapy enhances oxygenation and decreases the need for ECMO in newborns with hypoxemic respiratory failure. This review explores iNO
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Critical Care
Background:
- Persistent pulmonary hypertension of the newborn (PPHN) is a critical condition.
- Hypoxemic respiratory failure necessitates advanced respiratory support.
- Extracorporeal membrane oxygenation (ECMO) is a rescue therapy for severe cases.
Purpose of the Study:
- To review the current applications of inhaled nitric oxide (iNO) therapy in neonates.
- To evaluate the efficacy of iNO in improving oxygenation and reducing ECMO use.
- To explore the potential use of iNO in other pediatric patient groups.
Main Methods:
- Systematic review of existing literature on iNO therapy in newborns.
- Analysis of studies reporting oxygenation indices and need for mechanical ventilation or ECMO.
- Examination of data regarding iNO use in non-newborn pediatric populations.
Main Results:
- Inhaled nitric oxide therapy significantly improves oxygenation in term newborns with hypoxemic respiratory failure and PPHN.
- iNO therapy reduces the requirement for extracorporeal membrane oxygenation (ECMO) in this population.
- Evidence for iNO's role in other pediatric conditions is under investigation.
Conclusions:
- Inhaled nitric oxide is an established therapy for neonatal hypoxemic respiratory failure and PPHN.
- iNO offers a valuable alternative or adjunct to ECMO, improving outcomes.
- Further research is warranted to define the role of iNO in broader pediatric critical care settings.